IDH2 and chondrosarcoma: Targeting IDH mutations, lipid, glucose and mitochondrial metabolic targets, hedgehog, PI3K/Akt/MTOR, HIF and SRC pathways have yielded mixed results in clinical studies without clear therapeutic options in chondrosarcoma.